In 178 analysed allogeneic transplant recipients at higher cGVHD risk, prophylactic obinutuzumab vs placebo reduced 1-year steroid-requiring chronic GVHD (13.3% vs 35.2%; P=.0005); neutropenia was more common, with no difference in nonrelapse mortality.
RCTn = 178
Cutler et al. Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease